Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report

EL Rosenthal; JM Warram; E de Boer; JP Basilion; MA Biel; M Bogyo; M Bouvet; BE Brigman; YL Colson; SR DeMeester; GC Gurtner; T Ishizawa; PM Jacobs; Stijn Keereweer; JC Liao; QT Nguyen; JM Olson; KD Paulsen; D Rieves; BD Sumer; MF Tweedle; AL Vahrmeijer; JP Weichert; BC Wilson; MR Zenn; KR Zinn; GM van Dam

doi:10.2967/jnumed.115.158915

Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report

EL Rosenthal, JM Warram, E de Boer, JP Basilion, MA Biel, M Bogyo, M Bouvet, BE Brigman, YL Colson, SR DeMeester, GC Gurtner, T Ishizawa, PM Jacobs, Stijn Keereweer, JC Liao, QT Nguyen, JM Olson, KD Paulsen, D Rieves, BD SumerMF Tweedle, AL Vahrmeijer, JP Weichert, BC Wilson, MR Zenn, KR Zinn, GM van Dam

Otorhinolaryngology and Head and Neck Surgery

Research output: Contribution to journal › Article › Academic › peer-review

118 Citations (Scopus)

Abstract

Navigation with fluorescence guidance has emerged in the last decade as a promising strategy to improve the efficacy of oncologic surgery. To achieve routine clinical use, the onus is on the surgical community to objectively assess the value of this technique. This assessment may facilitate both Food and Drug Administration approval of new optical imaging agents and reimbursement for the imaging procedures. It is critical to characterize fluorescence-guided procedural benefits over existing practices and to elucidate both the costs and the safety risks. This report is the result of a meeting of the International Society of Image Guided Surgery (www.isigs.org) on February 6, 2015, in Miami, Florida, and reflects a consensus of the participants' opinions. Our objective was to critically evaluate the imaging platform technology and optical imaging agents and to make recommendations for successful clinical trial development of this highly promising approach in oncologic surgery.

Original language	Undefined/Unknown
Pages (from-to)	144-150
Number of pages	7
Journal	Journal of Nuclear Medicine
Volume	57
Issue number	1
DOIs	https://doi.org/10.2967/jnumed.115.158915
Publication status	Published - 2016

Research programs

EMC OR-01-62-02

Access to Document

10.2967/jnumed.115.158915

Cite this

Rosenthal, EL., Warram, JM., de Boer, E., Basilion, JP., Biel, MA., Bogyo, M., Bouvet, M., Brigman, BE., Colson, YL., DeMeester, SR., Gurtner, GC., Ishizawa, T., Jacobs, PM., Keereweer, S., Liao, JC., Nguyen, QT., Olson, JM., Paulsen, KD., Rieves, D., ... van Dam, GM. (2016). Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report. Journal of Nuclear Medicine, 57(1), 144-150. https://doi.org/10.2967/jnumed.115.158915

@article{b22a8aaec5e249488616c8fad62eb64c,

title = "Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report",

abstract = "Navigation with fluorescence guidance has emerged in the last decade as a promising strategy to improve the efficacy of oncologic surgery. To achieve routine clinical use, the onus is on the surgical community to objectively assess the value of this technique. This assessment may facilitate both Food and Drug Administration approval of new optical imaging agents and reimbursement for the imaging procedures. It is critical to characterize fluorescence-guided procedural benefits over existing practices and to elucidate both the costs and the safety risks. This report is the result of a meeting of the International Society of Image Guided Surgery (www.isigs.org) on February 6, 2015, in Miami, Florida, and reflects a consensus of the participants' opinions. Our objective was to critically evaluate the imaging platform technology and optical imaging agents and to make recommendations for successful clinical trial development of this highly promising approach in oncologic surgery.",

author = "EL Rosenthal and JM Warram and {de Boer}, E and JP Basilion and MA Biel and M Bogyo and M Bouvet and BE Brigman and YL Colson and SR DeMeester and GC Gurtner and T Ishizawa and PM Jacobs and Stijn Keereweer and JC Liao and QT Nguyen and JM Olson and KD Paulsen and D Rieves and BD Sumer and MF Tweedle and AL Vahrmeijer and JP Weichert and BC Wilson and MR Zenn and KR Zinn and {van Dam}, GM",

year = "2016",

doi = "10.2967/jnumed.115.158915",

language = "Undefined/Unknown",

volume = "57",

pages = "144--150",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine and Molecular Imaging",

number = "1",

}

Rosenthal, EL, Warram, JM, de Boer, E, Basilion, JP, Biel, MA, Bogyo, M, Bouvet, M, Brigman, BE, Colson, YL, DeMeester, SR, Gurtner, GC, Ishizawa, T, Jacobs, PM, Keereweer, S, Liao, JC, Nguyen, QT, Olson, JM, Paulsen, KD, Rieves, D, Sumer, BD, Tweedle, MF, Vahrmeijer, AL, Weichert, JP, Wilson, BC, Zenn, MR, Zinn, KR & van Dam, GM 2016, 'Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report', Journal of Nuclear Medicine, vol. 57, no. 1, pp. 144-150. https://doi.org/10.2967/jnumed.115.158915

TY - JOUR

T1 - Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report

AU - Rosenthal, EL

AU - Warram, JM

AU - de Boer, E

AU - Basilion, JP

AU - Biel, MA

AU - Bogyo, M

AU - Bouvet, M

AU - Brigman, BE

AU - Colson, YL

AU - DeMeester, SR

AU - Gurtner, GC

AU - Ishizawa, T

AU - Jacobs, PM

AU - Keereweer, Stijn

AU - Liao, JC

AU - Nguyen, QT

AU - Olson, JM

AU - Paulsen, KD

AU - Rieves, D

AU - Sumer, BD

AU - Tweedle, MF

AU - Vahrmeijer, AL

AU - Weichert, JP

AU - Wilson, BC

AU - Zenn, MR

AU - Zinn, KR

AU - van Dam, GM

PY - 2016

Y1 - 2016

N2 - Navigation with fluorescence guidance has emerged in the last decade as a promising strategy to improve the efficacy of oncologic surgery. To achieve routine clinical use, the onus is on the surgical community to objectively assess the value of this technique. This assessment may facilitate both Food and Drug Administration approval of new optical imaging agents and reimbursement for the imaging procedures. It is critical to characterize fluorescence-guided procedural benefits over existing practices and to elucidate both the costs and the safety risks. This report is the result of a meeting of the International Society of Image Guided Surgery (www.isigs.org) on February 6, 2015, in Miami, Florida, and reflects a consensus of the participants' opinions. Our objective was to critically evaluate the imaging platform technology and optical imaging agents and to make recommendations for successful clinical trial development of this highly promising approach in oncologic surgery.

AB - Navigation with fluorescence guidance has emerged in the last decade as a promising strategy to improve the efficacy of oncologic surgery. To achieve routine clinical use, the onus is on the surgical community to objectively assess the value of this technique. This assessment may facilitate both Food and Drug Administration approval of new optical imaging agents and reimbursement for the imaging procedures. It is critical to characterize fluorescence-guided procedural benefits over existing practices and to elucidate both the costs and the safety risks. This report is the result of a meeting of the International Society of Image Guided Surgery (www.isigs.org) on February 6, 2015, in Miami, Florida, and reflects a consensus of the participants' opinions. Our objective was to critically evaluate the imaging platform technology and optical imaging agents and to make recommendations for successful clinical trial development of this highly promising approach in oncologic surgery.

U2 - 10.2967/jnumed.115.158915

DO - 10.2967/jnumed.115.158915

M3 - Article

C2 - 26449839

SN - 0161-5505

VL - 57

SP - 144

EP - 150

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 1

ER -